Search
 
 
NEWS
 
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer - GSK
Dostarlimab Combination Shows Improved Endometrial Cancer Patient Survival at Trial Interim Analysis - Pharmacy Times